Antidepressants
Download
Report
Transcript Antidepressants
ANTIDEPRESSANTS
1
OUTLINE
Part II
Efficacy
Cipriani
STAR-D
(Lancet, 2009)
Side effect profile
Drug to drug
interactions
Comorbid anxiety
Treatment resistant
depression
(NEJM, 2009)
Special populations
Pregnant
women
Children
QTc
2
OUTLINE
Part I
SSRIs
TCAs
SNRIs
NaSSAs
MAOIs
NDRIs
3
SSRI
Prototype: Fluoxetine
Paroxetine, Fluvoxamine, Sertraline,
Citalopram, Escitalopram
4
SSRI: MOA
Deficiency of synaptic neurotransmitters
5HT,
NE, DA
5HT
Presynaptic
vesicles synaptic cleft
postsynaptic receptors reuptake transporters
presynaptically
Clinical efficacy is delayed a few weeks when
compared to other pharmacological action
5
6
SSRI: MOA
Downstream effects
Change
in receptor density
Downregulation
of inhibitory presynaptic autoreceptors
enhanced release of 5HT into synapse
Reorganization
of neurons
7
SSRI: PK, INDICATIONS, CONTRA
Usually long half-lives
Fluoxetine
longest (because of norfluoxetine
metabolite)
Indications: MDD, OCD, GAD, Panic Disorder,
Bulimia
Contraindications
SSRI
+ MAOIs – need a washout 2 weeks when
switching
8
SSRI: NOTES
Heterogenous group even though “SSRI” not
interchangeable
9
SSRI: NOTES
Citalopram – most serotonin selective, has H1
Fluoxetine and Sertraline – have affinity for D2
receptors
Paroxetine – has the most anticholinergic
10
TCA
Prototype: amitriptyline
Desipramine, imipramine, nortriptyline,
clomipramine, imipramine, doxepin, maprotiline
Nortriptyline
is a metabolite of amitriptyline
Desipramine is a metabolite of imipramine
11
TCA: MOA
TCAs inhibit the reuptake of 5HT and NA into
the presynaptic cell body
Antagonize many receptors: muscarinic,
histamine, adrenergic lots of side effects
12
TCA: MOA
Most serotonergic: clomipramine then
amitriptyline
Most noradrenergic: desipramine then
nortriptyline
Hits the most receptors and strongest:
amitriptyline
Hits weakest: desipramine (least histaminic)
Least α1: nortriptyline, desipramine
13
Most 5HT
Clomipiramine Amitriptyline
Most NA
Nortriptyline
Desipramine
Least H2
Least α1
14
TCA: NOTES
Group side effects by receptor profile
Anticholinergic: hot as a hare, dry as a bone,
mad as a hatter, blind as a bat
Orthostatic hypotension because of α1
Antimuscarinic: avoid with urinary retention,
BPH, closed angle glaucoma, increased IOP
15
TCA: NOTES
Cardiotoxic in overdose wide QRS heart
block often accompanied by hypotension
Slowly
absorbed so may present in ER with fatal
dose that has yet to be absorbed
Caution with suicidal patients
Cochrane 2007: As efficacious as SSRIs but
more side effects
16
SNRI
Prototype: Venlafaxine
Desvenlafaxine, duloxetine, milnacipran
17
SNRI
MOA: same story
PK: SNRIs shorter half-life compared to SSRI
Venlafaxine
has extended release form
Venlafaxine has an active metabolite, Odesmethylvenlafaxine. Both parent and metabolite
have lower clearance in liver and renal impairment
Venlafaxine: CYP450, esp CYP2D6
CYP2D6
is subject to polymorphisms metabolism
variable
18
SNRI
Taper gradually to avoid discontinuation
syndrome (more later)
19
NASSA
Mirtazapine
MOA:
Autoreceptor
and heteroreceptor blockade
presynaptically
5HT2 and 5HT3 antagonism postsynaptically
Leads
to enhanced 5HT1
5HT3 blockade explains less nausea and GI effects
Low
affinity for muscarinic and dopaminergic
receptors
High affinity for histaminic receptors
20
MAOI
MAO-A
Degrades
epi, norepi, serotonin, dopamine
Selective MAO-A inhibitor: Moclobemide
21
MAOI
MAO-B
Degrades
phenylethylamine, dopamine
Selective MAO-B inhibitor: Selegiline
Metabolites
of selegiline: L-amphetamine, Damphetamine
Parkinson’s
disease
MAO-B is non-selective at high doses
22
MAOI
Nonselective: Phenelzine
23
MAOI
Drug interaction with sympathomimetics
hypertensive crisis
24
MAOI
Foods with tyramine hypertensive crisis
Particularly
with MAO-A inhibitors
MAO-A in the gut breaks down tyramine which
stimulates norepi release
25
MAOI-A IN THE GUT
Norepinephrine
release
Tyramine
MAO- A
MAO- A inhibitor
Can be by-passed by use of a patch
26
MAOI
Drug interaction with sympathomimetics
hypertensive crisis
Foods with tyramine hypertensive crisis
Particularly
with MAO-A inhibitors
MAO-A in the gut breaks down tyramine which
stimulates norepi release
Disturbed REM, weight gain, postural
hypotension, sexual disturbances
27
NDRI
Prototype: Bupropion
DA and NA
?Nicotinic receptor antagonist
28
NDRI
Contraindications: seizure, MAOI’s, thioridazine
DA: smoking cessation
No 5HT: less sexual dysfunction
Wellbutrin vs Zyban
OR 1.9 vs placebo for smoking cessation
About Varenicline
29
PRINCIPLES OF PHARMACOTHERAPY
Thorough assessment
Suicidality, bipolarity, comorbidity, meds, features
(psychosis, atypicality, seasonality)
Laboratory assessment as indicated
Increase adherence
1-2 weeks initially, then every 2-4 weeks
Monitoring should include the use of validated scales
Choose according to sx profile, comorbidity, tolerability,
previous response, drug-drug interaction, cost, patient
preference
30
31
EFFICACY
SSRIs, SNRIs are safer and more tolerable than
TCAs and MAOIs
TCAs are second line
MAOIs are third line
NB:
Trazodone second-line – very sedating
Selegeline (MAO-Bi)- more tolerable but there are dietary restrictions
Quetiapine XR – good Level 1 evidence, but second line because of
tolerability and less data compared to SSRI’s
32
EFFICACY
33
EFFICACY
34
EFFICACY
VEMS:
Venlefaxine,
Escitalopram,
Mirtazapine,
Sertraline
Do not choose
Reboxetine
35
SIDE EFFECTS: SERIOUS ADVERSE EVENTS
Serotonin syndrome when SSRIs/SNRIs are
coadministered with MAOi
Increased risk of UGIB especially with NSAIDS
Osteoporosis and fractures in the elderly
Hyponatremia and agranulocytosis
Seizures
SSRIs
~0.4% compared to TCAs ~1.2%
Venlefaxine cardiotoxic in overdose
36
SIDE EFFECT PROFILE
37
SIDE EFFECT PROFILE
Venlefaxine
Good:
tremor, diarrhea, fatigue
Bad: nausea, insomnia, sedation, headache, dry
mouth, sweating, constipation, anxiety
Escitalopram
Least
side effects reported
38
SIDE EFFECT PROFILE
Mirtazapine
Bad:
>50% sedation, dry mouth, constipation
Sertraline
Bad:
headache, nausea, insomnia, sedation,
tremor, dry mouth, diarrhea, fatigue, anxiety
Good: sweating, constipation
39
SIDE EFFECT PROFILE
Focus on insomnia/CNS
Sleep
promoting: agomelatine, mirtazapine,
trazodone
Short-term BDZ or non-BDZ hypnotics in carefully
selected patients
May
also reduce nervousness and activation associated
with initiation of SSRI/SNRI antidepressants
40
SIDE EFFECT PROFILE
Focus on nausea/GI
Higher
with SSRIs/SNRIs that do not primarily inhibi
the serotonin reuptake transporter
Bupropion,
Mirtazapine, Moclobemide, Agomelatine
ER
is better than IR formulations
Most severe in first 2 weeks, then tolerance
Coadminister with ood, HS dosing, use of gastric
motility agents
41
SIDE EFFECT PROFILE
Focus on weight gain
Most
are weight neutral
Most weight gain with Mirtazapine and Paroxetine
during long term treatment
42
SIDE EFFECT PROFILE
Focus on sexual dysfunction
>30%
Fluoxetine,
fluvoxamine, paroxetine, sertraline
10-30%
Citalopram,
duloxetine, escitalopram, milnacipran,
venlefaxine
<10%
Agomelatine,
bupropion, mirtazapine,
moclobemide, reboxetine, selegeline
43
SIDE EFFECT PROFILE
Discontinuation syndrome
“FINISH”:
Flu-like symptoms, Insomnia, Nausea,
Imbalance, Sensory disturbances, and
Hyperarousal (anxiety/agitation)
Paroxetine, Venlafaxine
HR, SBP
Noradrenergic
blockade
LFT rise often not clinically relevant
44
DRUG TO DRUG INTERACTIONS
Highlights only. Table 7 of CanMAT on
pharmacotherapy.
Rifampin
may reduce AD efficacy (2C9, 2C19, 2D6)
Cipro and other fluoroquinolones may increase
duloxetine (1A2 inhibition)
Fluoxetine and paroxetine inhibit 2D6: codeine less
effective. Paroxetine increases propranolol.
Fluvoxamine increases warfarin and statins
(bleeding and rhabdo, respectively). 1A2. 2C19,
3A4
45
DRUG TO DRUG INTERACTIONS
Check
if patient are on
the following:
Antiepileptics
Methadone
Olanzapine
Quetiapine
Sildenafil
HIV
PI’s
Tamoxifen
Immune modulators
Macrolides
Beta-blockers
Amiodarone
Antiarrhythmics
Diltiazem,
verapamil
46
COMORBID ANXIETY
*Citalopram, escitalopram are effective but not Health Canada indicated in
2006 when guidelines were written.
47
COMORBID ANXIETY
Bupropion has not
been adequately
studied so not
recommended for
primary anxiety
disorders but has
been effective in
depression with
anxiety
48
TREATMENT RESISTANT DEPRESSION
Clinical lore: 2-4 weeks for tx effect
Studies: onset of response in 1-2 weeks
Patients with <20% improvement after 2 weeks
should have a change in tx such as a dose
increase
OSAC: optimise, switch, augment, combine
49
TREATMENT RESISTANT DEPRESSION
Ensure adherence
Re-evaluate diagnosis (bipolar II, psychotic
depression)
Re-assess comorbidity (anxiety, substance,
personality, medical conditions, chronic social
stressors)
Partial or no response – importance of scales
50
TREATMENT RESISTANT DEPRESSION
30% discontinue in 30 days
40% in 90 days
Must increase adherence
Education,
self-management, collaborative care
Therapeutic alliance
51
TREATMENT RESISTANT DEPRESSION
First line
Switch
to an agent with evidence for superiority
VEMS,
duloxetine, milnacipran
Add-on
Aripiprazole,
Lithium, Olanzapine, Risperidone
52
TREATMENT RESISTANT DEPRESSION
Second line
Add-on
Bupropion,
Mirtazapine, quetiapine, T3, another
antidepressant
Switch
for agents with superiority but side-effect
limitation
Amitriptyline,
clomipramine, MAOi
53
TREATMENT RESISTANT DEPRESSION
Third Line
Add-on
Buspirone,
modafinil, stimulants, ziprasidone
54
TREATMENT RESISTANT DEPRESSION
STAR*D
Open
label citalopram for 12 weeks, then switch
and combination arms
Response: 50% improvement
Of
those who responded, 56% in 8 weeks
Remission:
Of
back to normal levels
those with remission, 40% in 8 weeks
Thus
if improvement is minimal (>20%) after 4-6
weeks, continue for another 2-4 weeks before
considering other strategies
55
TREATMENT RESISTANT DEPRESSION
56
TREATMENT RESISTANT DEPRESSION
57
TREATMENT RESISTANT DEPRESSION
Number
needed to treat
is about 1:9 to
1:7, therefore,
reasonable
58
TREATMENT RESISTANT DEPRESSION
59
TRD ADD-ON SUMMARY
Level 1 evidence to support add-on treatment
with lithium and atypical antipsychotics for TRD
Level 2 support for T3
Level 3 evidence but also negative studies with
buspirone, methylphenidate, modafinil and
pindolol, so these agents are not
recommended as first or second-line
treatments.
60
TRD: ADJUVANT SUMMARY
Level 2 evidence to support efficacy of
antidepressant combinations in nonresponders to monotherapy
The best available evidence is for add-on
treatment with mirtazapine/mianserin or
bupropion
61
RISK FACTORS SUPPORTING LONG TERM
Older age
Recurrent episodes (3 or more)
Chronic episodes
Psychotic episodes
Severe episodes
Difficult to treat episodes
62
RISK FACTORS SUPPORTING LONG TERM
Significant comorbidity (psychiatric or medical)
Residual symptoms (lack of remission) during
current episode
History of recurrence during discontinuation of
antidepressants
63
SPECIAL POPULATIONS
Pregnant women
See CanMAT
ADs
do not appear to be major teratogens
1st
trimester use of paroxetine increased risk of cardiac
malformations
1st trimester use of fluoxetine not associated with
teratogenicity
64
SPECIAL POPULATIONS
Pregnant women
See CanMAT
?Increased
risk of spontaneous abortions
Depression
May
effect could not be ruled out
be associated with neonatal complications
PPH
Serotonergic
overstimulation, withdrawal,
neurobehavioural effects (?long-term)
65
SPECIAL POPULATIONS
Mom in the postpartum
Paroxetine
better than placebo for remission
Sertraline had a preventatitve effect in women with
prior hx of postpartum depression
66
SPECIAL POPULATIONS
Lactation
ADs
are in breast milk in usually small amounts
Nortripltyline, sertraline, paroxetine not detected in
infant serum levels
Fluoxetine higher risk of elevated serum levels
Citalopram – very little; equivocal studies
No effect on infant weight up to 18 mos
67
SPECIAL POPULATIONS
Children
TCAs
not effective in children
Citalopram and fluoxetine are favourable but effect
sizes are modest (NNT: 10)
Increased suicidal ideation/behaviours but NNH is
143
Venlafaxine
Best
has a higher risk estimate for suicidality
if AD is combined with CBT
68
SPECIAL POPULATIONS
Children and suicidality
In
summary, there is Level 1 evidence to support
modest efficacy of SSRI and SNRI antidepressants
in this age group, with most evidence for fluoxetine
and citalopram, and only a very small risk of
increased suicidality
Regardless, close monitoring is required when
using antidepressants in youth and young adults.
69
QTC
70
QTC
Citalopram
hERG
blockade by metabolite didesmethylcitalopram (DDCT)
Seen
in beagles, thought to be minor in humans
However,
2% of the US are cytochrome P450 2D6
ultrarapid and could have more DDCT
71
QTC
Fluoxetine
Also
inhibits hERG
But inhibits calcium channels = ? Protective
72
QTC
Though case reports have linked other SSRIs
with QTc prolongation, no prospective studies
have shown such agents to have a statistically
significant effect on the QTc
Overdose
reports
Few therapeutic dose studies
8 fluoxetine studies, 5 paroxetine studies = no
QTc prolongation
73